Delivery of RNAi therapeutics to the airways - From bench to bedside

Molecules

Volumn 21, Issue 9, 2016, Pages

  Qiu, Yingshan ^a   Lam, Jenny K W ^a   Leung, Susan W S ^a   Liang, Wanling ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Inhalation; MicroRNA (miRNA); Pulmonary delivery; Respiratory diseases; RNA interference; Short hairpin RNA (shRNA); Short interfering RNA (siRNA)

Indexed keywords

EID: 84988958977     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21091249     Document Type: Review

References (231)

1. Pilkington, G.; Boland, A.; Brown, T.; Oyee, J.; Bagust, A.; Dickson, R. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax 2015.
2. Borchers, A.T.; Chang, C.; Gershwin, M.E.; Gershwin, L.J. Respiratory syncytial virus-a comprehensive review. Clin. Rev. Allrgy Immunol. 2013, 45, 331-379.
3. Olaru, I.D.; von Groote-Bidlingmaier, F.; Heyckendorf, J.; Yew, W.W.; Lange, C.; Chang, K.C. Novel drugs against tuberculosis: A clinician's perspective. Eur. Respir. J. 2015, 45, 1119-1131.
4. Mushtaq, Y. The COPD pipeline. Nat. Rev. Drug Discov. 2014, 13, 253-254.
5. Olin, J.T.; Wechsler, M.E. Asthma: Pathogenesis and novel drugs for treatment. BMJ 2014, 349, g5517.
6. Rafii, R.; Juarez, M.M.; Albertson, T.E.; Chan, A.L. A review of current and novel therapies for idiopathic pulmonary fibrosis. J. Thorac. Dis. 2013, 5, 48-73.
7. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806-811.
8. Yoon, P.O.; Park, J.W.; Lee, C.M.; Kim, S.H.; Kim, H.N.; Ko, Y.; Bae, S.J.; Yun, S.; Park, J.H.; Kwon, T.; et al. Self-assembled micelle interfering RNA for effective and safe targeting of dysregulated genes in pulmonary fibrosis. J. Biol. Chem. 2016, 291, 6433-6446.
9. Ihara, D.; Hattori, N.; Horimasu, Y.; Masuda, T.; Nakashima, T.; Senoo, T.; Iwamoto, H.; Fujitaka, K.; Okamoto, H.; Kohno, N. Histological quantification of gene silencing by intratracheal administration of dry powdered small-interfering RNA/chitosan complexes in the murine lung. Pharm. Res. 2015, 32, 3877-3885.
10. Healey, G.D.; Lockridge, J.A.; Zinnen, S.; Hopkin, J.M.; Richards, I.; Walker, W. Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6. PLoS ONE 2014, 9, e90338.
11. Oh, B.; Lee, M. Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury. J. Control. Release 2014, 175, 25-35.
12. Zafra, M.P.; Mazzeo, C.; Gámez, C.; Marco, A.R.; de Zulueta, A.; Sanz, V.; Bilbao, I.; Ruiz-Cabello, J.; Zubeldia, J.M.; del Pozo, V. Gene silencing of SOCS3 by siRNA intranasal delivery inhibits asthma phenotype in mice. PLoS ONE 2014, 9, e91996.
13. Rosas-Taraco, A.G.; Higgins, D.M.; Sánchez-Campillo, J.; Lee, E.J.; Orme, I.M.; González-Juarrero, M. Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis 2011, 91, 98-106.
14. Lam, J.K.; Liang, W.; Chan, H.K. Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev. 2012, 64, 1-15.
15. Aagaard, L.; Rossi, J.J. RNAi therapeutics: Principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59, 75-86.
16. Karpala, A.J.; Doran, T.J.; Bean, A.G. Immune responses to dsRNA: Implications for gene silencing technologies. Immunol. Cell Biol. 2005, 83, 211-216.
17. Ozcan, G.; Ozpolat, B.; Coleman, R.L.; Sood, A.K.; Lopez-Berestein, G. Preclinical and clinical development of siRNA-based therapeutics. Adv. Drug Deliv. Rev. 2015, 87, 108-119.
18. Khatri, N.; Rathi, M.; Baradia, D.; Trehan, S.; Misra, A. In vivo delivery aspects of miRNA, shRNA and siRNA. Crit. Rev. Ther. Drug Carr. Syst. 2012, 29, 487-527.
19. Singh, S.; Narang, A.S.; Mahato, R.I. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm. Res. 2011, 28, 2996-3015.
20. Rao, D.D.; Vorhies, J.S.; Senzer, N.; Nemunaitis, J. siRNA vs. shRNA: Similarities and differences. Adv. Drug Deliv. Rev. 2009, 61, 746-759.
21. Lam, J.K.; Chow, M.Y.; Zhang, Y.; Leung, S.W. siRNA versus miRNA as therapeutics for gene silencing. Mol. Ther. Nucl. Acids 2015, 4, e252.
22. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509-524.
23. Shu, D.; Li, H.; Shu, Y.; Xiong, G.; Carson, W.E., III; Haque, F.; Xu, R.; Guo, P. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 2015, 9, 9731-9740.
24. McLendon, J.M.; Joshi, S.R.; Sparks, J.; Matar, M.; Fewell, J.G.; Abe, K.; Oka, M.; McMurtry, I.F.; Gerthoffer, W.T. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J. Control. Release 2015, 210, 67-75.
25. Ai, C.; Jiang, R.; Fu, L.; Chen, Y. MicroRNA-495 mimics delivery inhibits lung tumor progression. Tumour Biol. 2015, 36, 729-735.
26. Ma, D.; Lu, H.; Qu, Y.; Fu, W.; Ma, Z. Developing an effective therapeutic by delivery of synthetic microRNA-520e in lung cancer treatment. Biomed. Pharmacother. 2015, 69, 249-254.
27. Fujita, Y.; Kuwano, K.; Ochiya, T. Development of small RNA delivery systems for lung cancer therapy. Int. J. Mol. Sci. 2015, 16, 5254-5270.
28. Birmingham, A.; Anderson, E.; Sullivan, K.; Reynolds, A.; Boese, Q.; Leake, D.; Karpilow, J.; Khvorova, A. A protocol for designing siRNAs with high functionality and specificity. Nat. Protoc. 2007, 2, 2068-2078.
29. Bertrand, J.R.; Pottier, M.; Vekris, A.; Opolon, P.; Maksimenko, A.; Malvy, C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 2002, 296, 1000-1004.
30. Bobbin, M.L.; Rossi, J.J. RNA interference (RNAi)-based therapeutics: Delivering on the promise? Annu. Rev. Pharmacol. Toxicol. 2016, 56, 103-122.
31. Lundstrom, K. RNA-based drugs and vaccines. Expert Rev. Vaccines 2015, 14, 253-263.
32. Günther, M.; Lipka, J.; Malek, A.; Gutsch, D.; Kreyling, W.; Aigner, A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur. J. Pharm. Biopharm. 2011, 77, 438-449.
33. Paranjpe, M.; Müller-Goymann, C.C. Nanoparticle-mediated pulmonary drug delivery: A review. Int. J. Mol. Sci. 2014, 15, 5852-5873.
34. Carvalho, T.C.; Peters, J.I.; Williams, R.O. Influence of particle size on regional lung deposition-what evidence is there? Int. J. Pharm. 2011, 406, 1-10.
35. Sakagami, M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 2006, 58, 1030-1060.
36. Patton, J.S.; Byron, P.R. Inhaling medicines: Delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6, 67-74.
37. Merkel, O.M.; Rubinstein, I.; Kissel, T. siRNA delivery to the lung: What's new? Adv. Drug Deliv. Rev. 2014, 75, 112-128.
38. Fahy, J.V.; Dickey, B.F. Airway mucus function and dysfunction. N. Engl. J. Med. 2010, 363, 2233-2247.
39. Thornton, D.J.; Rousseau, K.; McGuckin, M.A. Structure and function of the polymeric mucins in airways mucus. Annu. Rev. Physiol. 2008, 70, 459-486.
40. Salathe, M. Regulation of mammalian ciliary beating. Annu. Rev. Physiol. 2007, 69, 401-422.
41. Lai, S.K.; Wang, Y.Y.; Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61, 158-171.
42. Parra, E.; Perez-Gil, J. Composition, structure and mechanical properties define performance of pulmonary surfactant membranes and films. Chem. Phys. Lipids 2015, 185, 153-175.
43. Duncan, J.E.; Whitsett, J.A.; Horowitz, A.D. Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in vitro. Hum. Gene Ther. 1997, 8, 431-438.
44. De Backer, L.; Braeckmans, K.; Demeester, J.; de Smedt, S.C.; Raemdonck, K. The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels. Nanomedicine 2013, 8, 1625-1638.
45. Benfer, M.; Kissel, T. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles. Eur. J. Pharm. Biopharm. 2012, 80, 247-256.
46. De Backer, L.; Braeckmans, K.; Stuart, M.C.; Demeester, J.; De Smedt, S.C.; Raemdonck, K. Bio-inspired pulmonary surfactant-modified nanogels: A promising siRNA delivery system. J. Control. Release 2015, 206, 177-186.
47. Haupenthal, J.; Baehr, C.; Kiermayer, S.; Zeuzem, S.; Piiper, A. Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem. Pharmacol. 2006, 71, 702-710.
48. Lipka, J.; Semmler-Behnke, M.; Wenk, A.; Burkhardt, J.; Aigner, A.; Kreyling, W. Biokinetic studies of non-complexed siRNA versus nano-sized PEI F25-LMW/siRNA polyplexes following intratracheal instillation into mice. Int. J. Pharm. 2016, 500, 227-235.
49. Man, D.K.; Chow, M.Y.; Casettari, L.; Gonzalez-Juarrero, M.; Lam, J.K. Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. Adv. Drug Deliv. Rev. 2016.
50. Mayor, S.; Parton, R.G.; Donaldson, J.G. Clathrin-independent pathways of endocytosis. Cold Spring Harb. Perspect. Biol. 2014, 6, 603-612.
51. Harush-Frenkel, O.; Debotton, N.; Benita, S.; Altschuler, Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 2007, 353, 26-32.
52. Wong, A.W.; Scales, S.J.; Reilly, D.E. DNA internalized via caveolae requires microtubule-dependent, Rab7-independent transport to the late endocytic pathway for delivery to the nucleus. J. Biol. Chem. 2007, 282, 22953-22963.
53. Khalil, I.A.; Kogure, K.; Futaki, S.; Harashima, H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem. 2006, 281, 3544-3551.
54. Vercauteren, D.; Piest, M.; van der Aa, L.J.; al Soraj, M.; Jones, A.T.; Engbersen, J.F.; de Smedt, S.C.; Braeckmans, K. Flotillin-dependent endocytosis and a phagocytosis-like mechanism for cellular internalization of disulfide-based poly(amido amine)/DNA polyplexes. Biomaterials 2011, 32, 3072-3084.
55. Vercauteren, D.; Rejman, J.; Martens, T.F.; Demeester, J.; de Smedt, S.C.; Braeckmans, K. On the cellular processing of non-viral nanomedicines for nucleic acid delivery: Mechanisms and methods. J. Control. Release 2012, 161, 566-581.
56. Zaki, N.M.; Tirelli, N. Gateways for the intracellular access of nanocarriers: A review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting. Expert Opin. Drug Deliv. 2010, 7, 895-913.
57. Gilleron, J.; Querbes, W.; Zeigerer, A.; Borodovsky, A.; Marsico, G.; Schubert, U.; Manygoats, K.; Seifert, S.; Andree, C.; Stoter, M.; et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 2013, 31, 638-646.
58. Dominska, M.; Dykxhoorn, D.M. Breaking down the barriers: SiRNA delivery and endosome escape. J. Cell Sci. 2010, 123, 1183-1189.
59. Ma, D. Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale 2014, 6, 6415-6425.
60. Varkouhi, A.K.; Scholte, M.; Storm, G.; Haisma, H.J. Endosomal escape pathways for delivery of biologicals. J. Control. Release 2011, 151, 220-228.
61. Liang, W.; Lam, J.K. Endosomal Escape Pathways for Non-Viral Nucleic Acid Delivery Systems. In Molecular Regulation of Endocytosis; Chapter 17; InTech: Rijeka, Croatia, 2012.
62. Dean, D.; Strong, D.; Zimmer, W. Nuclear entry of nonviral vectors. Gene Ther. 2005, 12, 881-890.
63. Ruigrok, M.; Frijlink, H.; Hinrichs, W. Pulmonary administration of small interfering RNA: The route to go? J. Control. Release 2016, 235, 14-23.
64. Youngren-Ortiz, S.R.; Gandhi, N.S.; España-Serrano, L.; Chougule, M.B. Aerosol delivery of siRNA to the lungs. Part 2: Nanocarrier-based delivery systems. Kona 2016.
65. Zhang, Y.; Satterlee, A.; Huang, L. In vivo gene delivery by nonviral vectors: Overcoming hurdles & quest. Mol. Ther. 2012, 20, 1298-1304.
66. Kanasty, R.; Dorkin, J.R.; Vegas, A.; Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 2013, 12, 967-977.
67. Yin, H.; Kanasty, R.L.; Eltoukhy, A.A.; Vegas, A.J.; Dorkin, J.R.; Anderson, D.G. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014, 15, 541-555.
68. Couto, L.B.; High, K.A. Viral vector-mediated RNA interference. Curr. Opin. Pharmacol. 2010, 10, 534-542.
69. Mueller, C.; Tang, Q.; Gruntman, A.; Blomenkamp, K.; Teckman, J.; Song, L.; Zamore, P.D.; Flotte, T.R. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol. Ther. 2012, 20, 590-600.
70. Chen, B.J.; Li, W.M.; Liu, D.; Zhnag, W. Construction of sh-rpS6 lentivirus vectors and its effect on proliferation in lung adenocarcinoma A549 cell lines. Sichuan Da Xue Xue Bao Yi Xue Ban 2014, 45, 293-298.
71. Liu, X.; Li, G.; Zhang, B.; Wang, L.; Li, X.H.; Li, X.P. Influence of suppression of Epstein-Barr Virus-encoded latent membrane protein 1 by rAAV vector mediated RNA interference on metastatic ability of nasopharyngeal cancer cells in vivo. Zhonghua Zhong Liu Za Zhi 2009, 31, 324-329.
72. Wu, C.J.; Huang, W.C.; Chen, L.C.; Shen, C.R.; Kuo, M.L. Pseudotyped adeno-associated virus 2/9-delivered CCL11 shRNA alleviates lung inflammation in an allergen-sensitized mouse model. Hum. Gene Ther. 2012, 23, 1156-1165.
73. Youngren-Ortiz, S.R.; Gandhi, N.S.; España-Serrano, L.; Chougule, M.B. Aerosol delivery of siRNA to the lungs. Part 1: Rationale for gene delivery systems. Kona 2016, 33, 63-85.
74. Zhang, S.; Zhi, D.; Huang, L. Lipid-based vectors for siRNA delivery. J. Drug Target. 2012, 20, 724-735.
75. Wang, J.-C.; Lai, S.; Guo, X.; Zhang, X.; de Crombrugghe, B.; Sonnylal, S.; Arnett, F.C.; Zhou, X. Attenuation of fibrosis in vitro and in vivo with SPARC siRNA. Arthritis Res. Ther. 2010, 12, R60.
76. Dalby, B.; Cates, S.; Harris, A.; Ohki, E.C.; Tilkins, M.L.; Price, P.J.; Ciccarone, V.C. Advanced transfection with Lipofectamine 2000 reagent: Primary neurons, siRNA, and high-throughput applications. Methods 2004, 33, 95-103.
77. Reich, S.J.; Fosnot, J.; Kuroki, A.; Tang, W.; Yang, X.; Maguire, A.M.; Bennett, J.; Tolentino, M.J. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 2003, 9, 210-216.
78. Vornlocher, H.-P. Antibody-directed cell-type-specific delivery of siRNA. Trends Mol. Med. 2006, 12, 1-3.
79. Lv, H.; Zhang, S.; Wang, B.; Cui, S.; Yan, J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 2006, 114, 100-109.
80. Neuberg, P.; Kichler, A. Recent developments in nucleic acid delivery with polyethylenimines. Adv. Genet. 2014, 88, 263-288.
81. Höbel, S.; Aigner, A. Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2013, 5, 484-501.
82. Nafee, N.; Taetz, S.; Schneider, M.; Schaefer, U.F.; Lehr, C.-M. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: Effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 2007, 3, 173-183.
83. Han, L.; Zhang, A.; Wang, H.; Pu, P.; Jiang, X.; Kang, C.; Chang, J. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum. Gene Ther. 2010, 21, 417-426.
84. Raemdonck, K.; Naeye, B.; Buyens, K.; Vandenbroucke, R.E.; Høgset, A.; Demeester, J.; de Smedt, S.C. Biodegradable dextran nanogels for RNA interference: Focusing on endosomal escape and intracellular siRNA delivery. Adv. Funct. Mater. 2009, 19, 1406-1415.
85. Howard, K.A.; Rahbek, U.L.; Liu, X.; Damgaard, C.K.; Glud, S.Z.; Andersen, M.Ø.; Hovgaard, M.B.; Schmitz, A.; Nyengaard, J.R.; Besenbacher, F. RNA interference in vitro and in vivo using a chitosan/siRNA nanoparticle system. Mol. Ther. 2006, 14, 476-484.
86. Liang, W.; Kwok, P.C.; Chow, M.Y.; Tang, P.; Mason, A.J.; Chan, H.-K.; Lam, J.K. Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. Eur. J. Pharm. Biopharm. 2014, 86, 64-73.
87. Shukla, R.S.; Qin, B.; Cheng, K. Peptides used in the delivery of small noncoding RNA. Mol. Pharm. 2014, 11, 3395-3408.
88. Li, H.; Tsui, T.Y.; Ma, W. Intracellular delivery of molecular cargo using cell-penetrating peptides and the combination strategies. Int. J. Mol. Sci. 2015, 16, 19518-19536.
89. Park, J.S.; Choi, Y.H.; Kim, S.W. Polyester Analogue of Poly-L-Lysine as a Soluble, Biodegradable Gene Delivery Carrier. U.S. Patent 6,217,912, 17 April 2001.
90. Hartono, S.B.; Gu, W.; Kleitz, F.; Liu, J.; He, L.; Middelberg, A.P.; Yu, C.; Lu, G.Q.; Qiao, S.Z. Poly-L-lysine functionalized large pore cubic mesostructured silica nanoparticles as biocompatible carriers for gene delivery. ACS Nano 2012, 6, 2104-2117.
91. Del Sorbo, L.; Costamagna, A.; Muraca, G.; Rotondo, G.; Civiletti, F.; Vizio, B.; Bosco, O.; Martin Conte, E.L.; Frati, G.; Delsedime, L.; et al. Intratracheal administration of small interfering RNA targeting fas reduces lung ischemia-reperfusion injury. Crit. Care Med. 2016, 44, e604-e613.
92. Das, S.; Kumar, M.; Negi, V.; Pattnaik, B.; Prakash, Y.S.; Agrawal, A.; Ghosh, B. MicroRNA-326 regulates profibrotic functions of transforming growth factor-β in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2014, 50, 882-892.
93. Fujita, Y.; Takeshita, F.; Kuwano, K.; Ochiya, T. RNAi therapeutic platforms for lung diseases. Pharmaceuticals 2013, 6, 223-250.
94. Reck, M.; Popat, S.; Reinmuth, N.; de Ruysscher, D.; Kerr, K.; Peters, S. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 25, 1-13.
95. Cohen, M.H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: Bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007, 12, 713-718.
96. Cohen, M.H.; Johnson, J.R.; Chattopadhyay, S.; Tang, S.; Justice, R.; Sridhara, R.; Pazdur, R. Approval summary: Erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist 2010, 15, 1344-1351.
97. Cohen, M.H.; Williams, G.A.; Sridhara, R.; Chen, G.; Pazdur, R. FDA drug approval summary: Gefitinib (ZD1839)(Iressa®) tablets. Oncologist 2003, 8, 303-306.
98. Landesman-Milo, D.; Ramishetti, S.; Peer, D. Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer Metastasis Rev. 2015, 34, 291-301.
99. Hong, S.-H.; Park, S.-J.; Lee, S.; Cho, C.S.; Cho, M.-H. Aerosol gene delivery using viral vectors and cationic carriers for in vivo lung cancer therapy. Expert Opin. Drug Deliv. 2015, 12, 977-991.
100. Brognard, J.; Clark, A.S.; Ni, Y.; Dennis, P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61, 3986-3997.
101. LA1 mice. Anticancer Res. 2015, 35, 2015-2019.
102. Hong, S.-H.; Kim, J.-E.; Kim, Y.-K.; Minai-Tehrani, A.; Shin, J.-Y.; Kang, B.; Kim, H.-J.; Cho, C.-S.; Chae, C.; Jiang, H.-L. Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1. Int. J. Nanomed. 2012, 7, 2293-2306.
103. Hwang, S.-K.; Chang, S.-H.; Minai-Tehrani, A.; Kim, Y.-S.; Cho, M.-H. Lentivirus-AIMP2-DX2 shRNA suppresses cell proliferation by regulating Akt1 signaling pathway in the lungs of AIMP2+/-Mice. J. Aerosol. Med. Pulm. Drug Deliv. 2013, 26, 165-173.
104. Tang, J.; Li, Y.; Eames, I.; Chan, P.; Ridgway, G. Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises. J. Hosp. Infect. 2006, 64, 100-114.
105. Xu, C.; Wang, P.; Zhang, J.; Tian, H.; Park, K.; Chen, X. Pulmonary codelivery of doxorubicin and siRNA by pH-sensitive nanoparticles for therapy of metastatic lung cancer. Small 2015, 11, 4321-4333.
106. Fujita, Y.; Takeshita, F.; Mizutani, T.; Ohgi, T.; Kuwano, K.; Ochiya, T. A novel platform to enable inhaled naked RNAi medicine for lung cancer. Sci. Rep. 2013, 3, 3325.
107. Conde, J.; Tian, F.; Hernández, Y.; Bao, C.; Cui, D.; Janssen, K.-P.; Ibarra, M.R.; Baptista, P.V.; Stoeger, T.; Jesús, M. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials 2013, 34, 7744-7753.
108. Hong, S.-H.; Minai-Tehrani, A.; Chang, S.-H.; Jiang, H.-L.; Lee, S.; Lee, A.-Y.; Seo, H.W.; Chae, C.; Beck, G.R., Jr.; Cho, M.-H. Knockdown of the sodium-dependent phosphate co-transporter 2b (NPT2b) suppresses lung tumorigenesis. PLoS ONE 2013, 8, e77121.
109. Okuda, T.; Kito, D.; Oiwa, A.; Fukushima, M.; Hira, D.; Okamoto, H. Gene silencing in a mouse lung metastasis model by an inhalable dry small interfering RNA powder prepared using the supercritical carbon dioxide technique. Biol. Pharm. Bull. 2013, 36, 1183-1191.
110. Taratula, O.; Kuzmov, A.; Shah, M.; Garbuzenko, O.B.; Minko, T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release 2013, 171, 349-357.
111. Soucek, L.; Whitfield, J.; Martins, C.P.; Finch, A.J.; Murphy, D.J.; Sodir, N.M.; Karnezis, A.N.; Swigart, L.B.; Nasi, S.; Evan, G.I. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455, 679-683.
112. Chen, A.M.; Zhang, M.; Wei, D.; Stueber, D.; Taratula, O.; Minko, T.; He, H. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5, 2673-2677.
113. Honma, K.; Iwao-Koizumi, K.; Takeshita, F.; Yamamoto, Y.; Yoshida, T.; Nishio, K.; Nagahara, S.; Kato, K.; Ochiya, T. RPN2 gene confers docetaxel resistance in breast cancer. Nat. Med. 2008, 14, 939-948.
114. Fujita, Y.; Yagishita, S.; Takeshita, F.; Yamamoto, Y.; Kuwano, K.; Ochiya, T. Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer. Oncotarget 2015, 6, 3335.
115. Lee, E.; Oh, C.; Kim, I.-S.; Kwon, I.C.; Kim, S. Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association. J. Control. Release 2015, 210, 105-114.
116. Zheng, C.; Zheng, M.; Gong, P.; Deng, J.; Yi, H.; Zhang, P.; Zhang, Y.; Liu, P.; Ma, Y.; Cai, L. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials 2013, 34, 3431-3438.
117. Li, L.; Gu, W.; Chen, J.; Chen, W.; Xu, Z.P. Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles. Biomaterials 2014, 35, 3331-3339.
118. Kang, M.H.; Reynolds, C.P. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15, 1126-1132.
119. Young, L.C.; Campling, B.G.; Cole, S.P.; Deeley, R.G.; Gerlach, J.H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. 2001, 7, 1798-1804.
120. Koli, U.; Krishnan, R.A.; Pofali, P.; Jain, R.; Dandekar, P. siRNA-based therapies for pulmonary diseases. J. Biomed. Nanotechnol. 2014, 10, 1953-1997.
121. Falsey, A.R.; Becker, K.L.; Swinburne, A.J.; Nylen, E.S.; Formica, M.A.; Hennessey, P.A.; Criddle, M.M.; Peterson, D.R.; Baran, A.; Walsh, E.E. Bacterial complications of respiratory tract viral illness: A comprehensive evaluation. J. Infect. Dis. 2013, 208, 432-441.
122. Lopez-Fraga, M.; Wright, N.; Jimenez, A. RNA interference-based therapeutics: New strategies to fight infectious disease. Infect. Disord. Drug Targets 2008, 8, 262-273.
123. Bitko, V.; Musiyenko, A.; Shulyayeva, O.; Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 2005, 11, 50-55.
124. Alvarez, R.; Elbashir, S.; Borland, T.; Toudjarska, I.; Hadwiger, P.; John, M.; Roehl, I.; Morskaya, S.S.; Martinello, R.; Kahn, J. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob. Agents Chemother. 2009, 53, 3952-3962.
125. Ge, Q.; Filip, L.; Bai, A.; Nguyen, T.; Eisen, H.N.; Chen, J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 2004, 101, 8676-8681.
126. Tompkins, S.M.; Lo, C.Y.; Tumpey, T.M.; Epstein, S.L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 2004, 101, 8682-8686.
127. Thomas, M.; Lu, J.J.; Ge, Q.; Zhang, C.; Chen, J.; Klibanov, A.M. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc. Natl. Acad. Sci. USA 2005, 102, 5679-5684.
128. Zhou, H.; Jin, M.; Yu, Z.; Xu, X.; Peng, Y.; Wu, H.; Liu, J.; Liu, H.; Cao, S.; Chen, H. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Res. 2007, 76, 186-193.
129. Zhou, K.; He, H.; Wu, Y.; Duan, M. RNA interference of avian influenza virus H5N1 by inhibiting viral mRNA with siRNA expression plasmids. J. Biotechnol. 2008, 135, 140-144.
130. Rosas-Taraco, A.G.; Higgins, D.M.; Sánchez-Campillo, J.; Lee, E.J.; Orme, I.M.; González-Juarrero, M. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am. J. Respir. Cell Mol. 2009, 41, 136-145.
131. Bitko, V.; Barik, S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 2001, 1, 34.
132. Ge, Q.; Eisen, H.N.; Chen, J. Use of siRNAs to prevent and treat influenza virus infection. Virus Res. 2004, 102, 37-42.
133. Stoppani, E.; Bassi, I.; Dotti, S.; Lizier, M.; Ferrari, M.; Lucchini, F. Expression of a single siRNA against a conserved region of NP gene strongly inhibits in vitro replication of different Influenza A virus strains of avian and swine origin. Antiviral Res. 2015, 120, 16-22.
134. Li, B.-J.; Tang, Q.; Cheng, D.; Qin, C.; Xie, F.Y.; Wei, Q.; Xu, J.; Liu, Y.; Zheng, B.-J.; Woodle, M.C. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 2005, 11, 944-951.
135. Ralston, S.L.; Lieberthal, A.S.; Meissner, H.C.; Alverson, B.K.; Baley, J.E.; Gadomski, A.M.; Johnson, D.W.; Light, M.J.; Maraqa, N.F.; Mendonca, E.A. Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014, 134, e1474-e1502.
136. Falsey, A.R.; Walsh, E.E. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 2000, 13, 371-384.
137. Falsey, A.R.; Hennessey, P.A.; Formica, M.A.; Cox, C.; Walsh, E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 2005, 352, 1749-1759.
138. Anderson, L.; Dormitzer, P.; Nokes, D.J.; Rappuoli, R.; Roca, A.; Graham, B. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013, 31, B209-B215.
139. DeVincenzo, J.; Cehelsky, J.E.; Alvarez, R.; Elbashir, S.; Harborth, J.; Toudjarska, I.; Nechev, L.; Murugaiah, V.; van Vliet, A.; Vaishnaw, A.K. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008, 77, 225-231.
140. DeVincenzo, J.; Lambkin-Williams, R.; Wilkinson, T.; Cehelsky, J.; Nochur, S.; Walsh, E.; Meyers, R.; Gollob, J.; Vaishnaw, A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl. Acad. Sci. USA 2010, 107, 8800-8805.
141. Alnylam Pharmaceuticals, Inc. Complete Results of Our ALN-RSV01 Phase IIb Study. Available online: http://www.alnylam.com/capella/presentations/complete-results-of-our-aln-rsv01-phase-iib-study/ (accessed on 9 April 2012).
142. Medina, R.A.; García-Sastre, A. Influenza A viruses: New research developments. Nat. Rev. Microbiol. 2011, 9, 590-603.
143. Dong, G.; Peng, C.; Luo, J.; Wang, C.; Han, L.; Wu, B.; Ji, G.; He, H. Adamantane-resistant influenza a viruses in the world (1902-2013): Frequency and distribution of M2 gene mutations. PLoS ONE 2015, 10, e0119115.
144. Samson, M.; Pizzorno, A.; Abed, Y.; Boivin, G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013, 98, 174-185.
145. Ge, Q.; McManus, M.T.; Nguyen, T.; Shen, C.-H.; Sharp, P.A.; Eisen, H.N.; Chen, J. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. USA 2003, 100, 2718-2723.
146. Hidalgo, A.; Cruz, A.; Pérez-Gil, J. Barrier or carrier? Pulmonary surfactant and drug delivery. Eur. J. Pharm. Biopharm. 2015, 95, 117-127.
147. Khantasup, K.; Kopermsub, P.; Chaichoun, K.; Dharakul, T. Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic Avian Influenza A (H5N1) virus infection. Antimicrob. Agents Chemother. 2014, 58, 2816-2824.
148. Sui, H.-Y.; Zhao, G.-Y.; Huang, J.-D.; Jin, D.-Y.; Yuen, K.-Y.; Zheng, B.-J. Small interfering RNA targeting M2 gene induces effective and long term inhibition of influenza A virus replication. PLoS ONE 2009, 4, e5671.
149. Liang, W.; Chow, M.Y.; Lau, P.N.; Zhou, Q.T.; Kwok, P.C.; Leung, G.P.; Mason, A.J.; Chan, H.-K.; Poon, L.L.; Lam, J.K. Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus. Mol. Pharm. 2015, 12, 910-921.
150. Robbins, M.; Judge, A.; Ambegia, E.; Choi, C.; Yaworski, E.; Palmer, L.; McClintock, K.; MacLachlan, I. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 2008, 19, 991-999.
151. WHO World Health Organization: Tuberculosis - Global TB Programme Core Functions. Available online: http://www.who.int/tb/publications/GTBcorporate-factsheet.pdf?ua=1 (accessed on 1 November 2015).
152. Kathania, M.; Raje, C.I.; Raje, M.; Dutta, R.K.; Majumdar, S. Bfl-1/A1 acts as a negative regulator of autophagy in mycobacteria infected macrophages. Int. J. Biochem. Cell Biol. 2011, 43, 573-585.
153. Roberts, E.A.; Chua, J.; Kyei, G.B.; Deretic, V. Higher order Rab programming in phagolysosome biogenesis. J. Cell Biol. 2006, 174, 923-929.
154. Wang, J.; Yang, K.; Zhou, L.; Wu, Y.; Zhu, M.; Lai, X.; Chen, T.; Feng, L.; Li, M.; Huang, C. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog. 2013, 9, e1003697.
155. Kim, J.K.; Yuk, J.-M.; Kim, S.Y.; Kim, T.S.; Jin, H.S.; Yang, C.-S.; Jo, E.-K. MicroRNA-125a inhibits autophagy activation and antimicrobial responses during mycobacterial infection. J. Immunol. 2015, 194, 5355-5365.
156. Behar, S.M.; Baehrecke, E.H. Tuberculosis: Autophagy is not the answer. Nature 2015, 528, 482-483.
157. Ramakrishnan, L. Revisiting the role of the granuloma in tuberculosis. Nat. Rev. Immunol. 2012, 12, 352-366.
158. Silva Miranda, M.; Breiman, A.; Allain, S.; Deknuydt, F.; Altare, F. The tuberculous granuloma: An unsuccessful host defence mechanism providing a safety shelter for the bacteria? Clin. Dev. Immunol. 2012, 139127.
159. Ordway, D.; Higgins, D.M.; Sanchez-Campillo, J.; Spencer, J.S.; Henao-Tamayo, M.; Harton, M.; Orme, I.M.; Juarrero, M.G. XCL1 (lymphotactin) chemokine produced by activated CD8 T cells during the chronic stage of infection with Mycobacterium tuberculosis negatively affects production of IFN-γ by CD4 T cells and participates in granuloma stability. J. Leukoc. Biol. 2007, 82, 1221-1229.
160. Toossi, Z.; Gogate, P.; Shiratsuchi, H.; Young, T.; Ellner, J.J. Enhanced production of TGF-beta by blood monocytes from patients with active tuberculosis and presence of TGF-beta in tuberculous granulomatous lung lesions. J. Immunol. 1995, 154, 465-473.
161. Bonecini-Almeida, M.G.; Ho, J.L.; Boéchat, N.; Huard, R.C.; Chitale, S.; Doo, H.; Geng, J.; Rego, L.; Lazzarini, L.C.O.; Kritski, A.L. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor β (TGF-β) and analysis of TGF-β receptors I and II in active tuberculosis. Infect. Immun. 2004, 72, 2628-2634.
162. Perl, M.; Lomas-Neira, J.; Venet, F.; Chung, C.-S.; Ayala, A. Pathogenesis of indirect (secondary) acute lung injury. Expert Rev. Respir. Med. 2011, 5, 115-126.
163. Barnes, P.J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 2008, 8, 183-192.
164. Parekh, D.; Dancer, R.C.; Thickett, D.R. Acute lung injury. Clin. Med. 2011, 11, 615-618.
165. Khaitov, M.R.; Shilovskiy, I.P.; Nikonova, A.A.; Shershakova, N.N.; Kamyshnikov, O.Y.; Babakhin, A.A.; Zverev, V.V.; Johnston, S.L.; Khaitov, R.M. Small interfering RNAs targeted to Interleukin-4 and Respiratory Syncytial Virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation. Hum. Gene Ther. 2014, 25, 642-650.
166. Darcan-Nicolaisen, Y.; Meinicke, H.; Fels, G.; Hegend, O.; Haberland, A.; Kühl, A.; Loddenkemper, C.; Witzenrath, M.; Kube, S.; Henke, W. Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice. J. Immunol. 2009, 182, 7501-7508.
167. h2 inflammation via the miR-1-Mpl (myeloproliferative leukemia virus oncogene)-P-selectin axis. J. Exp. Med. 2013, 210, 1993-2010.
168. Goh, F.Y.; Cook, K.L.; Upton, N.; Tao, L.; Lah, L.C.; Leung, B.P.; Wong, W.F. Receptor-interacting protein 2 gene silencing attenuates allergic airway inflammation. J. Immunol. 2013, 191, 2691-2699.
169. Kumar, M.; Ahmad, T.; Sharma, A.; Mabalirajan, U.; Kulshreshtha, A.; Agrawal, A.; Ghosh, B. Let-7 microRNA-mediated regulation of IL-13 and allergic airway inflammation. J. Allergy Clin. Immunol. 2011, 128, 1077-1085.
170. Lee, C.-C.; Huang, H.-Y.; Chiang, B.-L. Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness. Mol. Ther. 2008, 16, 60-65.
171. Asai-Tajiri, Y.; Matsumoto, K.; Fukuyama, S.; Kan-o, K.; Nakano, T.; Tonai, K.; Ohno, T.; Azuma, M.; Inoue, H.; Nakanishi, Y. Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma. Respir. Res. 2014, 15, 132.
172. Huang, Z.-Y.; Kim, M.-K.; Kim-Han, T.-H.; Indik, Z.K.; Schreiber, A.D. Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma. Mol. Immunol. 2013, 53, 52-59.
173. Wu, W.; Chen, H.; Li, Y.-M.; Wang, S.-Y.; Diao, X.; Liu, K.-G. Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma. Int. J. Clin. Exp. Pathol. 2014, 7, 5505-5514.
174. Xie, Y.; Kim, N.H.; Nadithe, V.; Schalk, D.; Thakur, A.; Kiliç, A.; Lum, L.G.; Bassett, D.J.; Merkel, O.M. Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J. Control. Release 2016, 229, 120-129.
175. Lomas-Neira, J.; Perl, M.; Venet, F.; Chung, C.S.; Ayala, A. The role and source of tumor necrosis factor-α in hemorrhage-induced priming for septic lung injury. Shock 2012, 37, 611-620.
176. Edwards, M.R.; Bartlett, N.W.; Clarke, D.; Birrell, M.; Belvisi, M.; Johnston, S.L. Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol. Ther. 2009, 121, 1-13.
177. Wenzel, S.E. Asthma: Defining of the persistent adult phenotypes. Lancet 2006, 368, 804-813.
178. WHO. The Global Asthma Report 2014. Available online: http://www.globalasthmareport.org/ (accessed on 30 October 2014).
179. Chung, K.F.; Wenzel, S.E.; Brozek, J.L.; Bush, A.; Castro, M.; Sterk, P.J.; Adcock, I.M.; Bateman, E.D.; Bel, E.H.; Bleecker, E.R. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2013, 43, 343-373.
180. Likhar, N.; Kanukula, R.; Mothe, R.; Vsn, M.; Dang, A. Investigating the value of omalizumab in the treatment of severe persistent allergic asthma: A systematic review of cost-effectiveness studies. Value Health 2016, 19, A115.
181. Khaitov, M.; Shilovskiy, I.; Nikonova, A.; Shershakova, N.; Kamyshnikov, O.; Babakhin, A.; Zverev, V.; Johnston, S.; Khaitov, R. siRNAs targeted to IL-4 and RSV reduce airway inflammation in a mouse model of virus-induced asthma exacerbation. Hum. Gene Ther. 2014, 25, 642-650.
182. Xie, Y.; Merkel, O.M. Pulmonary delivery of siRNA via polymeric vectors as therapies of asthma. Arch. Pharm. 2015, 348, 681-688.
183. Lloyd, C.M.; Hessel, E.M. Functions of T cells in asthma: More than just TH2 cells. Nat. Rev. Immunol. 2010, 10, 838-848.
184. Larché, M.; Robinson, D.S.; Kay, A.B. The role of T lymphocytes in the pathogenesis of asthma. J. Allergy Clin. Immunol. 2003, 111, 450-463.
185. Wenzel, S.; Ford, L.; Pearlman, D.; Spector, S.; Sher, L.; Skobieranda, F.; Wang, L.; Kirkesseli, S.; Rocklin, R.; Bock, B. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 2013, 368, 2455-2466.
186. Hodsman, P.; Ashman, C.; Cahn, A.; de Boever, E.; Locantore, N.; Serone, A.; Pouliquen, I. A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br. J. Clin. Pharmacol. 2013, 75, 118-128.
187. Brightling, C.E.; Chanez, P.; Leigh, R.; O'Byrne, P.M.; Korn, S.; She, D.; May, R.D.; Streicher, K.; Ranade, K.; Piper, E. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 2015, 3, 692-701.
188. Castro, M.; Wenzel, S.E.; Bleecker, E.R.; Pizzichini, E.; Kuna, P.; Busse, W.W.; Gossage, D.L.; Ward, C.K.; Wu, Y.; Wang, B. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: A phase 2b randomised dose-ranging study. Lancet Respir. Med. 2014, 2, 879-890.
189. Kubo, M.; Inoue, H. Suppressor of cytokine signaling 3 (SOCS3) in Th2 cells evokes Th2 cytokines, IgE, and eosinophilia. Curr. Allergy Asthma Rep. 2006, 6, 32-39.
190. Busse, W.W.; Lemanske, R.F.; Gern, J.E. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010, 376, 826-834.
191. Tak, P.P.; Firestein, G.S. NF-κB: A key role in inflammatory diseases. J. Clin. Investig. 2001, 107, 7-11.
192. Gagliardo, R.; Chanez, P.; Mathieu, M.; Bruno, A.; Costanzo, G.; Gougat, C.; Vachier, I.; Bousquet, J.; Bonsignore, G.; Vignola, A.M. Persistent activation of nuclear factor-κB signaling pathway in severe uncontrolled asthma. Am. J. Respir. Crit. Care Med. 2003, 168, 1190-1198.
193. Finotto, S.; de Sanctis, G.T.; Lehr, H.A.; Herz, U.; Buerke, M.; Schipp, M.; Bartsch, B.; Atreya, R.; Schmitt, E.; Galle, P.R. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J. Exp. Med. 2001, 193, 1247-1260.
194. Wong, W.F. Inhibitors of the tyrosine kinase signaling cascade for asthma. Curr. Opin. Pharmacol. 2005, 5, 264-271.
195. Wong, W.F.; Leong, K.P. Tyrosine kinase inhibitors: A new approach for asthma. Biochim. Biophys. Acta Proteins Proteom. 2004, 1697, 53-69.
196. Guntur, V.P.; Reinero, C.R. The potential use of tyrosine kinase inhibitors in severe asthma. Curr. Opin. Allergy Clin. Immunol. 2012, 12, 68-75.
197. Matsubara, S.; Koya, T.; Takeda, K.; Joetham, A.; Miyahara, N.; Pine, P.; Masuda, E.S.; Swasey, C.H.; Gelfand, E.W. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am. J. Respir. Cell Mol. 2006, 34, 426-433.
198. Stenton, G.R.; Ulanova, M.; Déry, R.E.; Merani, S.; Kim, M.-K.; Gilchrist, M.; Puttagunta, L.; Musat-Marcu, S.; James, D.; Schreiber, A.D. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J. Immunol. 2002, 169, 1028-1036.
199. Watts, J.K.; Corey, D.R. Clinical status of duplex RNA. Bioorgan. Med. Chem. Lett. 2010, 20, 3203-3207.
200. Burnett, J.C.; Rossi, J.J.; Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 2011, 6, 1130-1146.
201. Hammad, H.; Lambrecht, B.N. Dendritic cells and epithelial cells: Linking innate and adaptive immunity in asthma. Nat. Rev. Immunol. 2008, 8, 193-204.
202. h2 effector responses in a mouse model of asthma. J. Allergy Clin. Immunol. 2004, 114, 166-173.
203. Kim, N.; Nadithe, V.; Elsayed, M.; Merkel, O. Tracking and treating activated T cells. J. Drug Deliv. Sci. Technol. 2013, 23, 17-21.
204. Jaffar, Z.H.; Stanciu, L.; Pandit, A.; Lordan, J.; Holgate, S.T.; Roberts, K. Essential role for both CD80 and CD86 costimulation, but not CD40 interactions, in allergen-induced Th2 cytokine production from asthmatic bronchial tissue: Role for αβ, but not γδ, T cells. J. Immunol. 1999, 163, 6283-6291.
205. Vestbo, J.; Hurd, S.S.; Agustí, A.G.; Jones, P.W.; Vogelmeier, C.; Anzueto, A.; Barnes, P.J.; Fabbri, L.M.; Martinez, F.J.; Nishimura, M. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013, 187, 347-365.
206. Barnes, P.J. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest Med. 2014, 35, 71-86.
207. Cosio, M.G.; Saetta, M.; Agusti, A. Immunologic aspects of chronic obstructive pulmonary disease. N. Engl. J. Med. 2009, 360, 2445-2454.
208. Vlahos, R.; Bozinovski, S. Recent advances in pre-clinical mouse models of COPD. Clin. Sci. 2014, 126, 253-265.
209. Fujisawa, T.; Velichko, S.; Thai, P.; Hung, L.-Y.; Huang, F.; Wu, R. Regulation of airway MUC5AC expression by IL-1β and IL-17A; the NF-κB paradigm. J. Immunol. 2009, 183, 6236-6243.
210. Ezzie, M.E.; Crawford, M.; Cho, J.-H.; Orellana, R.; Zhang, S.; Gelinas, R.; Batte, K.; Yu, L.; Nuovo, G.; Galas, D. Gene expression networks in COPD: MicroRNA and mRNA regulation. Thorax 2012, 67, 122-131.
211. Mizuno, S.; Bogaard, H.J.; Gomez-Arroyo, J.; Alhussaini, A.; Kraskauskas, D.; Cool, C.D.; Voelkel, N.F. MicroRNA-199a-5p is associated with hypoxia-inducible factor-1α expression in lungs from patients with COPD. Chest 2012, 142, 663-672.
212. Tsushima, K.; King, L.S.; Aggarwal, N.R.; de Gorordo, A.; D'Alessio, F.R.; Kubo, K. Acute lung injury review. Intern. Med. 2009, 48, 621-630.
213. Ware, L.B.; Matthay, M.A. The acute respiratory distress syndrome. N. Engl. J. Med. 2000, 342, 1334-1349.
214. Matthay, M.A.; Ware, L.B.; Zimmerman, G.A. The acute respiratory distress syndrome. J. Clin. Investig. 2012, 122, 2731-2740.
215. Perl, M.; Chung, C.-S.; Lomas-Neira, J.; Rachel, T.-M.; Biffl, W.L.; Cioffi, W.G.; Ayala, A. Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am. J. Pathol. 2005, 167, 1545-1559.
216. Patel, B.V.; Wilson, M.R.; O'Dea, K.P.; Takata, M. TNF-induced death signaling triggers alveolar epithelial dysfunction in acute lung injury. J. Immunol. 2013, 190, 4274-4282.
217. Zhao, Y.; Gorshkova, I.A.; Berdyshev, E.; He, D.; Fu, P.; Ma, W.; Su, Y.; Usatyuk, P.V.; Pendyala, S.; Oskouian, B. Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression. Am. J. Respir. Cell Mol. Biol. 2011, 45, 426-435.
218. Holgate, S.T. Innate and adaptive immune responses in asthma. Nat. Med. 2012, 18, 673-683.
219. Zhao, Y.; Zheng, Z.; Cohen, C.J.; Gattinoni, L.; Palmer, D.C.; Restifo, N.P.; Rosenberg, S.A.; Morgan, R.A. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 2006, 13, 151-159.
220. Reber, L.; da Silva, C.A.; Frossard, N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur. J. Pharmacol. 2006, 533, 327-340.
221. Maneechotesuwan, K.; Yao, X.; Ito, K.; Jazrawi, E.; Usmani, O.S.; Adcock, I.M.; Barnes, P.J. Suppression of GATA-3 nuclear import and phosphorylation: A novel mechanism of corticosteroid action in allergic disease. PLoS Med. 2009, 6, e1000076.
222. Wynn, T.A. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 2011, 208, 1339-1350.
223. Wilson, M.; Wynn, T. Pulmonary fibrosis: Pathogenesis, etiology and regulation. Mucosal. Immunol. 2009, 2, 103-121.
224. D'Alessandro-Gabazza, C.N.; Kobayashi, T.; Boveda-Ruiz, D.; Takagi, T.; Toda, M.; Gil-Bernabe, P.; Miyake, Y.; Yasukawa, A.; Matsuda, Y.; Suzuki, N.; et al. Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2012, 46, 397-406.
225. Sung, D.K.; Kong, W.H.; Park, K.; Kim, J.H.; Kim, M.Y.; Kim, H.; Hahn, S.K. Noncovalenly PEGylated CTGF siRNA/PDMAEMA complex for pulmonary treatment of bleomycin-induced lung fibrosis. Biomaterials 2013, 34, 1261-1269.
226. Bhowmick, N.A.; Chytil, A.; Plieth, D.; Gorska, A.E.; Dumont, N.; Shappell, S.; Washington, M.K.; Neilson, E.G.; Moses, H.L. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303, 848-851.
227. Lee, C.-M.; Park, J.W.; Cho, W.-K.; Zhou, Y.; Han, B.; Yoon, P.O.; Chae, J.; Elias, J.A.; Lee, C.G. Modifiers of TGF-β1 effector function as novel therapeutic targets of pulmonary fibrosis. Korean J. Intern. Med. 2014, 29, 281-290.
228. Zhou, Y.; Lee, J.-Y.; Lee, C.-M.; Cho, W.-K.; Kang, M.-J.; Koff, J.L.; Yoon, P.-O.; Chae, J.; Park, H.-O.; Elias, J.A. Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis. J. Biol. Chem. 2012, 287, 41991-42000.
229. Chow, M.Y.T.; Lam, J.K.W. Dry powder formulation of plasmid DNA and siRNA for inhalation. Curr. Pharm. Des. 2015, 21, 3854-3866.
230. DeVincenzo, J.P. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir. Ther. 2012, 17, 213.
231. Zamora, M.R.; Budev, M.; Rolfe, M.; Gottlieb, J.; Humar, A.; DeVincenzo, J.; Vaishnaw, A.; Cehelsky, J.; Albert, G.; Nochur, S. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. Respir. Crit. Care Med. 2011, 183, 531-538.